Navigation Links
EYLEA™ (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
Date:6/28/2011

s and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the Sanofi and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended March 31, 2011.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Bayer Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer website at
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
2. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
3. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
4. Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation
5. Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
8. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
9. Reverse NanoJapan: Rice to host 25-30 Japanese students
10. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
11. Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... The Europe Thermal Protective Clothing ... provide crucial revenue forecasts. It estimates the market ... a CAGR of 7.5%, from 2013 to 2018. ... Thermal Protective Clothing market report for a glimpse ... by various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
(Date:11/27/2014)... 2014 Calcivis, a medical ... tooth decay, today announces that it has completed ... Activity Imaging System. The Calcivis Caries ... and consumable combination designed to transform the assessment ... involves a unique, proprietary bioluminescence approach combined with ...
(Date:11/26/2014)... 26, 2014 2014 Deep Research ... professional and in-depth research report on the Ammonium ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/26/2014)... HOUSTON and PHILADELPHIA , ... the most demanding and unforgiving environments. Human exploration of ... cognitive performance to ensure mission safety and success, and ... cognitive performance for mission success, little is known about ... aspects of cognition are primarily affected. Now, ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4
... Fla. , Jan. 15 Andrew P. ... Foundation and diabetes advocate announced today that he will be ... a biotechnology company that has developed and patented a family ... and cosmetic industries. , "I,m really excited about their ...
... , Jan. 14 /PRNewswire-FirstCall/ - Medical International Technology Inc. ... that it has received clearance by FINRA to be traded on ... posted for trading on the OTC Bulletin Board at the opening ... MDLH.OB. , This is very positive news for all existing and ...
... ... Scholarships. The first is a two-year scholarship to be awarded to a graduating ... sponsor four scholarships for community-active, graduating Lake Braddock High School seniors. , ... Manassas, VA (PRWEB) January 13, ...
Cached Biology Technology:Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board 2MIT is pleased to announce that it has received clearance by FINRA to be listed on the OTC Bulletin Board "MDLH.OB" 2RiVIdium Inc. Creates Five Local Scholarships 2
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... and the Montreal Neurological Institute (MNI), McGill University have ... survival also play an active and major role in ... published this week in The Journal of Neuroscience ... variety of acute and chronic neurological disorders, including glaucoma ...
... impact on them caused by humanity,s carbon emissions. ... used coral from the Great Barrier Reef to reveal ... due to human activity. Professor Malcolm McCulloch, a ... Reef Studies and Australian National University today receives Australia,s ...
... (Nasdaq: AWRE ), a leading supplier of broadband ... first quarter ended March 31, 2009. Revenues for the ... 22% compared to $5.9 million in the same quarter last ... diluted net income per share in accordance with U.S. generally ...
Cached Biology News:Cell's split personality is a major discovery into neurological diseases 2Coral 'can't escape the heat' 2Aware, Inc. Reports First Quarter 2009 Financial Results 2Aware, Inc. Reports First Quarter 2009 Financial Results 3Aware, Inc. Reports First Quarter 2009 Financial Results 4Aware, Inc. Reports First Quarter 2009 Financial Results 5Aware, Inc. Reports First Quarter 2009 Financial Results 6
Human PDGF, CF...
... The mycobacteria in ... cells to the injection site which enhances ... Freund's Adjuvant is used for the initial ... the subsequent boosts. Antigens (preferably in saline) ...
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: